The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Open accessAbstract
Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., & Jit, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00306-8 · Cited by 1,288
Self-citationIncreasing Vaccination: Putting Psychological Science Into Action
Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2017) · Psychological Science in the Public Interest · doi:10.1177/1529100618760521 · Cited by 1,233
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19
Neumann-Böhme, S., Varghese, N. E., Sabat, I., Barros, P. P., Brouwer, W., van Exel, J., Schreyögg, J., & Stargardt, T. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01208-6 · Cited by 1,011
Covid-19 vaccine hesitancy among ethnic minority groups
Razai, M. S., Osama, T., McKechnie, D. G. J., & Majeed, A. (2021) · BMJ · doi:10.1136/bmj.n513 · Cited by 481
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Calina, D., Docea, A., Petrakis, D., Egorov, A., Ishmukhametov, A., Gabibov, A., Shtilman, M., Kostoff, R., Carvalho, F., Vinceti, M., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4596 · Cited by 318
Ensuring global access to COVID-19 vaccines
Yamey, G., Schäferhoff, M., Hatchett, R., Pate, M., Zhao, F., & McDade, K. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30763-7 · Cited by 298
Cited by
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab381 · Cited by 511
Karki, R., Lee, S., Mall, R., Pandian, N., Wang, Y., Sharma, B. R., Malireddi, R. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 350
Metadata
- Authors
- Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E.
- Venue
- Health Policy
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 125
- Issue
- 5
- Pages
- 553-567
- ISSN
- 0168-8510 (ISSN-L)
- OpenAlex
- W3147728765
- Cited by
- 307
- References
- 30
- FWCI
- 19.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 vaccine challenges: What have we learned so far and what remains to be done? https://app.cochat.ai/papers/10.1016/j.healthpol.2021.03.013
- The paper
- Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy. https://doi.org/10.1016/j.healthpol.2021.03.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.